Core Viewpoint - The FDA has approved Milestone's CARDAMYST nasal spray, marking a significant milestone for the company and its product portfolio [2]. Group 1: Company Overview - Milestone's President and CEO, Joe Oliveto, will provide opening remarks and discuss the product label details during the conference call [4]. - Dr. David Bharucha, the Chief Medical Officer, will address the medical need from a clinician's perspective [4]. - Lorenz Muller, the Chief Commercial Officer, will outline the launch plans for CARDAMYST nasal spray [4].

Company Overview - Milestone Pharmaceuticals Inc. (MIST) has received approval for its first commercial product, CARDAMYST nasal spray, aimed at converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [1][3]. Product Details - CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker designed for self-administration during unpredictable episodes of PSVT, marking the first FDA-approved treatment for this condition in over 30 years [3]. - The product is expected to be available in retail pharmacies by the first quarter of 2026 [3]. Market Context - PSVT affects more than two million Americans, with episodes characterized by rapid heart rates ranging from 160 to over 250 beats per minute, often occurring suddenly [2]. - Symptoms associated with PSVT include palpitations, sweating, chest pressure or pain, shortness of breath, sudden fatigue, fainting, and anxiety [2]. Stock Performance - On January 29, 2025, MIST was trading around $1.98, and it reached a 52-week high of $3.06 during intraday trading on December 12, 2025, before closing at $2.41, reflecting an 18.31% decline [4].